Keyword Analysis & Research: revolution medicines kras g12d


Keyword Analysis

Keyword CPC PCC Volume Score Length of keyword
revolution medicines kras g12d1.590.486718630
revolution0.620.753824110
medicines1.210.92433349
kras0.030.89115564
g12d1.180.98481164

Keyword Research: People who searched revolution medicines kras g12d also searched

Keyword CPC PCC Volume Score
revolution medicines kras g12d0.060.3552785

Search Results related to revolution medicines kras g12d on Search Engine

  • KRAS - Wikipedia

    wikipedia.org

    https://en.wikipedia.org/wiki/KRAS

    The most common KRAS mutation is G12D which is estimated to be present in up to 37% pancreatic cancers and over 12% of colorectal cancers. Normally amino acid position 12 of the KRAS protein is occupied by glycine but in G12D it is occupied by aspartic acid. ... Revolution Medicines is currently exploring a small molecule therapy and has ...

    DA: 5 PA: 11 MOZ Rank: 15

  • Revolution Medicines Looks to Raise $200M in Public Offering

    precisiononcologynews.com

    https://www.precisiononcologynews.com/business-news/revolution-medicines-looks-raise-200m-public-offering

    Jul 20, 2022 · The financing would support the clinical development of Revolution's RAS inhibitors currently in the clinic, RMC-6236, and help advance its preclinical RAS(ON) programs into the clinic, including its KRAS G12C inhibitor RMC-6291, KRAS G12D inhibitor RMC-9805, and KRAS G13C inhibitor RMC-8839.

    DA: 52 PA: 9 MOZ Rank: 26

  • Revolution Medicines Appoints Lorence Kim, M.D ... - BioSpace

    biospace.com

    https://www.biospace.com/article/releases/revolution-medicines-appoints-lorence-kim-m-d-accomplished-health-care-industry-leader-to-board-of-directorsboard-composition-evolves-as-company-s-development-pipeline-matures/

    Jul 13, 2022 · Revolution Medicines Appoints Lorence Kim, M.D., Accomplished Health Care Industry Leader, to Board of Directors - read this article along with other careers information, tips and advice on BioSpace ... RMC-9805 (KRAS G12D) and RMC-8839 (KRAS G13C), and a pipeline of research compounds targeting additional RAS variants. RAS Companion Inhibitors ...

    DA: 97 PA: 28 MOZ Rank: 14

  • Investor Relations | Revolution Medicines, Inc.

    revmed.com

    https://ir.revmed.com/

    Aug 09, 2022 · The Investor Relations website contains information about Revolution Medicines, Inc.'s business for stockholders, potential investors, and financial analysts ... RMC-6291 (KRAS G12C), RMC-9805 (KRAS G12D) and RMC-8839 (KRAS G13C), and a pipeline of research compounds targeting additional RAS variants. RAS Companion Inhibitors in clinical ...

    DA: 87 PA: 33 MOZ Rank: 54

  • Revolution Medicines looks to raise $230M in new public offering

    endpts.com

    https://endpts.com/revolution-medicines-shares-tumble-as-company-looks-to-raise-230m-in-new-public-offering/

    Jul 20, 2022 · Mark Goldsmith, Revolution Medicines CEO (Mark Kauzlarich/Bloomberg via Getty Images) ... KRAS G12C, KRAS G12D, KRAS G13C and more. The can­di­date for RAS mul­ti, known as RMC-6236, has just ...

    DA: 19 PA: 38 MOZ Rank: 26

  • Therapeutic KRAS G12C inhibition drives effective interferon

    science.org

    https://www.science.org/doi/10.1126/sciadv.abm8780

    Jul 20, 2022 · Lung cancer is the number one cause of cancer deaths worldwide, leading to some 1.8 million deaths annually, and therefore represents a disease of very high unmet need ().Non–small cell lung cancer (NSCLC) comprises 84% of all lung cancers and has a 5-year survival rate of only 25% ().Fortunately, with the introduction of immune checkpoint blockade …

    DA: 55 PA: 6 MOZ Rank: 8

  • Revolution Medicines Reports Second Quarter 2022 Financial …

    wallstreet-online.de

    https://www.wallstreet-online.de/nachricht/15800331-revolution-medicines-reports-second-quarter-2022-financial-results-and-update-on-corporate-progress

    2 days ago · Revolution Medicines Reports Second Quarter 2022 Financial Results and Update on Corporate Progress ... RMC-9805 is an oral, selective, covalent inhibitor of KRAS G12D (ON), ...

    DA: 99 PA: 8 MOZ Rank: 68

  • Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) - Investors Hub

    advfn.com

    https://ih.advfn.com/stock-market/NASDAQ/revolution-medicines-RVMD/stock-news/88637125/prospectus-filed-pursuant-to-rule-424b5-424b5

    Jul 20, 2022 · Revolution Medicines ... RMC-9805 is designed as a first-in-class, potent, oral and selective tri-complex inhibitor of KRAS G12D (ON). It is designed to exhibit low nanomolar potency for suppressing RAS pathway signaling and growth of KRAS G12D-bearing cancer cells and is engineered to covalently inactivate KRAS G12D for irreversible inhibition.

    DA: 75 PA: 37 MOZ Rank: 67

  • The KRAS-G12C inhibitor: activity and resistance

    nature.com

    https://www.nature.com/articles/s41417-021-00383-9

    Sep 01, 2021 · In contrast, RM-018, a representative KRAS-G12C-selective inhibitor from Revolution Medicines’ new class of RAS(ON) inhibitors, retains potent inhibitory activity against tumor cells harboring ...

    DA: 97 PA: 6 MOZ Rank: 99

  • G12C突变难造「药王」，KRAS靶点需要冲破适应症天花板

    pedaily.cn

    https://news.pedaily.cn/202207/497018.shtml

    Jul 28, 2022 · 实际上，Mirati公司针对KRAS G12D突变已经有所进展。 ... 目前，包括勃林格殷格翰和Revolution Medicines等海外药企，便沿着这一思路寻找答案，逻辑基本 ...

    DA: 44 PA: 14 MOZ Rank: 33